Immuneering Corporation (NASDAQ:IMRX) Receives Consensus Rating of “Moderate Buy” from Analysts

Immuneering Corporation (NASDAQ:IMRX) has been assigned an average recommendation of “Moderate Buy” from the eight ratings firms that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, six have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $16.50.

Several analysts have weighed in on the stock. Needham & Company LLC upped their price objective on shares of Immuneering from $8.00 to $11.00 and gave the stock a “buy” rating in a research note on Monday, September 15th. Chardan Capital reissued a “buy” rating and issued a $20.00 target price on shares of Immuneering in a report on Thursday, November 13th. Leerink Partnrs upgraded Immuneering to a “strong-buy” rating in a research report on Friday, October 31st. Leerink Partners started coverage on Immuneering in a report on Friday, October 31st. They set an “outperform” rating and a $15.00 price target for the company. Finally, Mizuho set a $12.00 price objective on Immuneering in a research note on Wednesday, October 29th.

Immuneering Stock Performance

Shares of NASDAQ IMRX opened at $6.72 on Wednesday. Immuneering has a 52-week low of $1.10 and a 52-week high of $10.08. The business has a fifty day moving average of $6.62 and a two-hundred day moving average of $5.72. The stock has a market cap of $433.91 million, a PE ratio of -3.78 and a beta of 0.48.

Immuneering (NASDAQ:IMRX) last announced its earnings results on Wednesday, November 12th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.01). Analysts predict that Immuneering will post -1.86 earnings per share for the current year.

Institutional Investors Weigh In On Immuneering

Hedge funds have recently added to or reduced their stakes in the stock. Jane Street Group LLC acquired a new stake in Immuneering in the 1st quarter valued at about $32,000. China Universal Asset Management Co. Ltd. bought a new stake in shares of Immuneering during the third quarter valued at approximately $35,000. Future Financial Wealth Managment LLC acquired a new stake in shares of Immuneering in the third quarter valued at approximately $35,000. Kingsview Wealth Management LLC acquired a new stake in shares of Immuneering in the second quarter valued at approximately $47,000. Finally, Mercer Global Advisors Inc. ADV bought a new position in Immuneering in the 3rd quarter worth approximately $70,000. Institutional investors own 67.65% of the company’s stock.

About Immuneering

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.